Oxalyl chloride → N-(5-tert-butyl-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinopyrimidin-4-yloxy)naphthalen-1-yl)-2-oxoacetamide
反応式
[N:1]1([C:7]2[N:12]=[C:11]([O:13][C:14]3[C:23]4[C:18](=[CH:19][CH:20]=[CH:21][CH:22]=4)[C:17]([C:24](=[O:28])[C:25]([OH:27])=O)=[CH:16][CH:15]=3)[CH:10]=[CH:9][N:8]=2)[CH2:6][CH2:5][O:4][CH2:3][CH2:2]1.C(Cl)(=O)C(Cl)=O.[NH2:35][C:36]1[C:37]([O:51][CH3:52])=[C:38]([NH:46][S:47]([CH3:50])(=[O:49])=[O:48])[CH:39]=[C:40]([C:42]([CH3:45])([CH3:44])[CH3:43])[CH:41]=1.CCN(C(C)C)C(C)C>C(Cl)Cl.CN(C=O)C>[C:42]([C:40]1[CH:39]=[C:38]([NH:46][S:47]([CH3:50])(=[O:49])=[O:48])[C:37]([O:51][CH3:52])=[C:36]([NH:35][C:25](=[O:27])[C:24]([C:17]2[C:18]3[C:23](=[CH:22][CH:21]=[CH:20][CH:19]=3)[C:14]([O:13][C:11]3[CH:10]=[CH:9][N:8]=[C:7]([N:1]4[CH2:6][CH2:5][O:4][CH2:3][CH2:2]4)[N:12]=3)=[CH:15][CH:16]=2)=[O:28])[CH:41]=1)([CH3:45])([CH3:43])[CH3:44]参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
[4-(2-Morpholin-4-yl-pyrimidin-4-yl-oxy)-naphthalen-1-yl]-oxo-acetic acid (16) obtained above (36 mg, 0.095 mmol) was dissolved in 2 mL DCM and oxalyl chloride (0.08 mL, 0.949 mmol) was added, followed by catalytic DMF. The reaction mixture was stirred at rt, after which N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide (14) (26 mg, 0.096 mmol) and DIEA (0.05 mL, 0.284 mmol) were added, and stirring was continued for 12 hr. The reaction mixture was concentrated in vacuo and the residue was purified by LC/MS (10-100% AcN/H2O over 8.5 min.) Calculated mass=444. Observed mass=444.
後処理
- stirringstirring
- concentrationThe reaction mixture was concentrated in vacuo
- customthe residue was purified by LC/MS (10-100% AcN/H2O over 8.5 min.)
出典と根拠
- ORDレコード
- ord-fd08995cf32043a2b4ac89b48fd0b29d
- 出典データセット
- uspto-grants-2010_07
- 特許番号
- US07749999B2
反応ノート
読み込み中…